{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:11:52Z","timestamp":1793938312531,"version":"4.8.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T00:00:00Z","timestamp":1704931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001230","name":"Macquarie University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001230","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Surviv"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Breast cancer is the most diagnosed cancer in women with chemotherapy being a common treatment. Toxicities due to chemotherapy can result in dose reduction, delay, and early cessation of treatment, which along with causing distress for individuals during their cancer treatment might also reduce the therapeutic effect. The purpose of this systematic review is to examine the role of body composition on chemotherapy toxicities in women with breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic search of the literature was completed on electronic databases Pubmed, Embase, CINHAHL, and Cochrane. Studies were included if the direct effect of body composition on chemotherapy toxicities was reported and excluded if body composition could not be isolated. A critical appraisal of the studies included was performed using McMasters University Critical Review Form for Quantitative Studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eleven studies were included with a total of 2881 female participants. All studies reported significant relationships between body composition and chemotherapy toxicities; however, individual parameters differed between the studies. Adding to the heterogeneity, different thresholds were reported to determine both sarcopenia and myosteatosis, making it difficult to identify a common finding.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This review suggests that body composition may be an important factor in predicting the severity of chemotherapy toxicities during treatment for breast cancer; however, the lack of international consensus as to thresholds in the literature for sarcopenia and myosteatosis may result in bias. The review supports the need for further prospective studies, allowing for more robust, pre-determined data collection, to better understand the implications of body composition on toxicities and benefits of using body composition to individualize chemotherapy dosing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Implications for Cancer Survivors<\/jats:title>\n                    <jats:p>Toxicities due to chemotherapy can result in treatment being unable to be completed as planned, potentially resulting in poorer survival outcomes. Improved knowledge in this area may give rise to a more reliable way of individualizing chemotherapy dosage to help mitigate this risk.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11764-023-01512-z","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T07:01:47Z","timestamp":1704956507000},"page":"914-929","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Body composition and chemotherapy toxicities in breast cancer: a systematic review of the literature"],"prefix":"10.1007","volume":"19","author":[{"given":"Lori","family":"Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhiannon","family":"Stellmaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Koelmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,11]]},"reference":[{"issue":"6","key":"1512_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [published correction appears in CA Cancer J Clin. 2020 Jul;70(4):313]. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492.","journal-title":"CA Cancer J Clin."},{"issue":"1130","key":"1512_CR2","doi-asserted-by":"publisher","first-page":"20211033","DOI":"10.1259\/bjr.20211033","volume":"95","author":"L Wilkinson","year":"2022","unstructured":"Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022;95(1130):20211033. https:\/\/doi.org\/10.1259\/bjr.20211033.","journal-title":"Br J Radiol."},{"key":"1512_CR3","unstructured":"World Health Organization. Breast cancer. 2021. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer"},{"issue":"4","key":"1512_CR4","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.ctrv.2008.01.007","volume":"34","author":"HM Coley","year":"2008","unstructured":"Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev. 2008;34(4):378\u201390. https:\/\/doi.org\/10.1016\/j.ctrv.2008.01.007.","journal-title":"Cancer Treat Rev."},{"issue":"2","key":"1512_CR5","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.hoc.2007.03.001","volume":"21","author":"EL Mayer","year":"2007","unstructured":"Mayer EL, Burstein HJ. Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am. 2007;21(2):257\u201372. https:\/\/doi.org\/10.1016\/j.hoc.2007.03.001.","journal-title":"Hematol Oncol Clin North Am."},{"issue":"12","key":"1512_CR6","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.3390\/cancers11121822","volume":"11","author":"M Garc\u00eda-Aranda","year":"2019","unstructured":"Garc\u00eda-Aranda M, Redondo M. Immunotherapy: a challenge of breast cancer treatment. Cancers (Basel). 2019;11(12):1822. Published 2019 Nov 20. https:\/\/doi.org\/10.3390\/cancers11121822.","journal-title":"Cancers (Basel)."},{"issue":"7","key":"1512_CR7","doi-asserted-by":"publisher","first-page":"e0132853","DOI":"10.1371\/journal.pone.0132853","volume":"10","author":"L Rossi","year":"2015","unstructured":"Rossi L, Stevens D, Pierga JY, et al. Impact of adjuvant chemotherapy on breast cancer survival: a real-world population. PLoS One. 2015;10(7):e0132853. Published 2015 Jul 27. https:\/\/doi.org\/10.1371\/journal.pone.0132853.","journal-title":"PLoS One."},{"key":"1512_CR8","volume-title":"Cancer chemotherapy","author":"MT Amjad","year":"2023","unstructured":"Amjad MT, Chidharla A, Kasi A. Cancer chemotherapy. In StatPearls: StatPearls Publishing; 2023."},{"key":"1512_CR9","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.critrevonc.2019.02.005","volume":"136","author":"KA Bland","year":"2019","unstructured":"Bland KA, Zadravec K, Landry T, Weller S, Meyers L, Campbell KL. Impact of exercise on chemotherapy completion rate: a systematic review of the evidence and recommendations for future exercise oncology research. Crit Rev Oncol Hematol. 2019;136:79\u201385. https:\/\/doi.org\/10.1016\/j.critrevonc.2019.02.005.","journal-title":"Crit Rev Oncol Hematol."},{"issue":"13","key":"1512_CR10","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1016\/s0959-8049(02)00151-x","volume":"38","author":"A Felici","year":"2002","unstructured":"Felici A, Verweij J, Sparreboom A. Dosing strategies for anticancer drugs: the good, the bad and body-surface area. Eur J Cancer. 2002;38(13):1677\u201384. https:\/\/doi.org\/10.1016\/s0959-8049(02)00151-x.","journal-title":"Eur J Cancer."},{"issue":"6","key":"1512_CR11","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1097\/FTD.0000000000001029","volume":"44","author":"RHL Hoge","year":"2022","unstructured":"Hoge RHL, Detert Oude Weme SEH, Vervenne WL, et al. Lean body mass and total body weight versus body surface area as a determinant of docetaxel pharmacokinetics and toxicity. Ther Drug Monit. 2022;44(6):755\u201361. https:\/\/doi.org\/10.1097\/FTD.0000000000001029.","journal-title":"Ther Drug Monit."},{"issue":"1","key":"1512_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clon.2006.10.010","volume":"19","author":"SA Kaestner","year":"2007","unstructured":"Kaestner SA, Sewell GJ. Chemotherapy dosing part I: scientific basis for current practice and use of body surface area. Clin Oncol (R Coll Radiol). 2007;19(1):23\u201337. https:\/\/doi.org\/10.1016\/j.clon.2006.10.010.","journal-title":"Clin Oncol (R Coll Radiol)."},{"issue":"4","key":"1512_CR13","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/jcsm.12436","volume":"10","author":"S Kurk","year":"2019","unstructured":"Kurk S, Peeters P, Stellato R, et al. Skeletal muscle mass loss and dose-limiting toxicities in metastatic colorectal cancer patients. J Cachexia Sarcopenia Muscle. 2019;10(4):803\u201313. https:\/\/doi.org\/10.1002\/jcsm.12436.","journal-title":"J Cachexia Sarcopenia Muscle."},{"issue":"8","key":"1512_CR14","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1634\/theoncologist.12-8-913","volume":"12","author":"RH Mathijssen","year":"2007","unstructured":"Mathijssen RH, de Jong FA, Loos WJ, van der Bol JM, Verweij J, Sparreboom A. Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference? Oncologist. 2007;12(8):913\u201323. https:\/\/doi.org\/10.1634\/theoncologist.12-8-913.","journal-title":"Oncologist."},{"issue":"2","key":"1512_CR15","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/bcp.14628","volume":"87","author":"BC Sallustio","year":"2021","unstructured":"Sallustio BC, Boddy AV. Is there scope for better individualisation of anthracycline cancer chemotherapy? Br J Clin Pharmacol. 2021;87(2):295\u2013305. https:\/\/doi.org\/10.1111\/bcp.14628.","journal-title":"Br J Clin Pharmacol."},{"key":"1512_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.pharmthera.2018.12.003","volume":"196","author":"M Hilmi","year":"2019","unstructured":"Hilmi M, Jouinot A, Burns R, et al. Body composition and sarcopenia: the next-generation of personalized oncology and pharmacology? Pharmacol Ther. 2019;196:135\u201359. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.12.003.","journal-title":"Pharmacol Ther."},{"issue":"39","key":"1512_CR17","doi-asserted-by":"publisher","first-page":"25714","DOI":"10.18632\/oncotarget.25394","volume":"9","author":"F Mazzuca","year":"2018","unstructured":"Mazzuca F, Onesti CE, Roberto M, et al. Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines. Oncotarget. 2018;9(39):25714\u201322. https:\/\/doi.org\/10.18632\/oncotarget.25394.","journal-title":"Oncotarget."},{"issue":"10191","key":"1512_CR18","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1016\/S0140-6736(19)31138-9","volume":"393","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. 2019;393(10191):2636\u201346. https:\/\/doi.org\/10.1016\/S0140-6736(19)31138-9.","journal-title":"Lancet."},{"issue":"12","key":"1512_CR19","doi-asserted-by":"publisher","first-page":"M716","DOI":"10.1093\/gerona\/55.12.m716","volume":"55","author":"R Roubenoff","year":"2000","unstructured":"Roubenoff R, Hughes VA. Sarcopenia: current concepts. J Gerontol A Biol Sci Med Sci. 2000;55(12):M716\u201324. https:\/\/doi.org\/10.1093\/gerona\/55.12.m716.","journal-title":"J Gerontol A Biol Sci Med Sci."},{"key":"1512_CR20","doi-asserted-by":"publisher","first-page":"101883","DOI":"10.1016\/j.arr.2023.101883","volume":"86","author":"G Coletta","year":"2023","unstructured":"Coletta G, Phillips SM. An elusive consensus definition of sarcopenia impedes research and clinical treatment: a narrative review. Ageing Res Rev. 2023;86:101883. https:\/\/doi.org\/10.1016\/j.arr.2023.101883.","journal-title":"Ageing Res Rev."},{"issue":"1","key":"1512_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis [published correction appears in Age Ageing. 2019 Jul 1;48(4):601]. Age Ageing. 2019;48(1):16\u201331. https:\/\/doi.org\/10.1093\/ageing\/afy169.","journal-title":"Age Ageing."},{"issue":"1","key":"1512_CR22","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/jcsm.13115","volume":"14","author":"J Zanker","year":"2023","unstructured":"Zanker J, Sim M, Anderson K, et al. Consensus guidelines for sarcopenia prevention, diagnosis and management in Australia and New Zealand. J Cachexia Sarcopenia Muscle. 2023;14(1):142\u201356. https:\/\/doi.org\/10.1002\/jcsm.13115.","journal-title":"J Cachexia Sarcopenia Muscle."},{"issue":"5","key":"1512_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.18773\/austprescr.2017.053","volume":"40","author":"M Barras","year":"2017","unstructured":"Barras M, Legg A. Drug dosing in obese adults. Aust Prescr. 2017;40(5):189\u201393. https:\/\/doi.org\/10.18773\/austprescr.2017.053.","journal-title":"Aust Prescr."},{"key":"1512_CR24","doi-asserted-by":"publisher","first-page":"110539","DOI":"10.1016\/j.nut.2019.06.020","volume":"67","author":"AM Ryan","year":"2019","unstructured":"Ryan AM, Prado CM, Sullivan ES, Power DG, Daly LE. Effects of weight loss and sarcopenia on response to chemotherapy, quality of life, and survival. Nutrition. 2019;67:110539. https:\/\/doi.org\/10.1016\/j.nut.2019.06.020.","journal-title":"Nutrition."},{"issue":"3","key":"1512_CR25","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s10549-019-05352-3","volume":"177","author":"GFP Aleixo","year":"2019","unstructured":"Aleixo GFP, Williams GR, Nyrop KA, Muss HB, Shachar SS. Muscle composition and outcomes in patients with breast cancer: meta-analysis and systematic review. Breast Cancer Res Treat. 2019;177(3):569\u201379. https:\/\/doi.org\/10.1007\/s10549-019-05352-3.","journal-title":"Breast Cancer Res Treat."},{"key":"1512_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.clnesp.2019.04.004","volume":"32","author":"LP da Cunha","year":"2019","unstructured":"da Cunha LP, Silveira MN, Mendes MCS, et al. Sarcopenia as an independent prognostic factor in patients with metastatic colorectal cancer: a retrospective evaluation. Clin Nutr ESPEN. 2019;32:107\u201312. https:\/\/doi.org\/10.1016\/j.clnesp.2019.04.004.","journal-title":"Clin Nutr ESPEN."},{"issue":"3","key":"1512_CR27","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ejso.2014.11.040","volume":"41","author":"BH Tan","year":"2015","unstructured":"Tan BH, Brammer K, Randhawa N, et al. Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. Eur J Surg Oncol. 2015;41(3):333\u20138. https:\/\/doi.org\/10.1016\/j.ejso.2014.11.040.","journal-title":"Eur J Surg Oncol."},{"issue":"9","key":"1512_CR28","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1093\/annonc\/mdx271","volume":"28","author":"F Bozzetti","year":"2017","unstructured":"Bozzetti F. Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy. Ann Oncol. 2017;28(9):2107\u201318. https:\/\/doi.org\/10.1093\/annonc\/mdx271.","journal-title":"Ann Oncol."},{"issue":"4","key":"1512_CR29","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.clnu.2011.12.011","volume":"31","author":"R Thibault","year":"2012","unstructured":"Thibault R, Genton L, Pichard C. Body composition: why, when and for who? Clin Nutr. 2012;31(4):435\u201347. https:\/\/doi.org\/10.1016\/j.clnu.2011.12.011.","journal-title":"Clin Nutr."},{"issue":"4","key":"1512_CR30","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s13244-015-0414-0","volume":"6","author":"C Yip","year":"2015","unstructured":"Yip C, Dinkel C, Mahajan A, Siddique M, Cook GJ, Goh V. Imaging body composition in cancer patients: visceral obesity, sarcopenia and sarcopenic obesity may impact on clinical outcome. Insights into imaging. 2015;6(4):489\u201397. https:\/\/doi.org\/10.1007\/s13244-015-0414-0.","journal-title":"Insights into imaging."},{"key":"1512_CR31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.compmedimag.2019.04.007","volume":"75","author":"S Dabiri","year":"2019","unstructured":"Dabiri S, Popuri K, Cespedes Feliciano EM, Caan BJ, Baracos VE, Beg MF. Muscle segmentation in axial computed tomography (CT) images at the lumbar (L3) and thoracic (T4) levels for body composition analysis. Comput Med Imaging Graph. 2019;75:47\u201355. https:\/\/doi.org\/10.1016\/j.compmedimag.2019.04.007.","journal-title":"Comput Med Imaging Graph."},{"issue":"2","key":"1512_CR32","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ejso.2014.10.056","volume":"41","author":"G Malietzis","year":"2015","unstructured":"Malietzis G, Aziz O, Bagnall NM, Johns N, Fearon KC, Jenkins JT. The role of body composition evaluation by computerized tomography in determining colorectal cancer treatment outcomes: a systematic review. Eur J Surg Oncol. 2015;41(2):186\u201396. https:\/\/doi.org\/10.1016\/j.ejso.2014.10.056.","journal-title":"Eur J Surg Oncol."},{"issue":"5","key":"1512_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/jim-2018-000722","volume":"66","author":"M Borga","year":"2018","unstructured":"Borga M, West J, Bell JD, et al. Advanced body composition assessment: from body mass index to body composition profiling. J Investig Med. 2018;66(5):1\u20139. https:\/\/doi.org\/10.1136\/jim-2018-000722.","journal-title":"J Investig Med."},{"issue":"5","key":"1512_CR34","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1097\/MCO.0b013e32830b5f23","volume":"11","author":"SY Lee","year":"2008","unstructured":"Lee SY, Gallagher D. Assessment methods in human body composition. Curr Opin Clin Nutr Metab Care. 2008;11(5):566\u201372. https:\/\/doi.org\/10.1097\/MCO.0b013e32830b5f23.","journal-title":"Curr Opin Clin Nutr Metab Care."},{"key":"1512_CR35","volume-title":"Guidelines for critical review of the literature: quantitative studies","author":"M Law","year":"1998","unstructured":"Law M, et al. Guidelines for critical review of the literature: quantitative studies. Hamilton: McMasters University; 1998."},{"issue":"9","key":"1512_CR36","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/j.jsams.2015.11.005","volume":"19","author":"EL Pressick","year":"2016","unstructured":"Pressick EL, Gray MA, Cole RL, Burkett BJ. A systematic review on research into the effectiveness of group-based sport and exercise programs designed for Indigenous adults. J Sci Med Sport. 2016;19(9):726\u201332. https:\/\/doi.org\/10.1016\/j.jsams.2015.11.005.","journal-title":"J Sci Med Sport."},{"issue":"1","key":"1512_CR37","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40279-019-01219-1","volume":"50","author":"B Thompson","year":"2020","unstructured":"Thompson B, Almarjawi A, Sculley D, Janse de Jonge X. The effect of the menstrual cycle and oral contraceptives on acute responses and chronic adaptations to resistance training: a systematic review of the literature. Sports Med. 2020;50(1):171\u201385. https:\/\/doi.org\/10.1007\/s40279-019-01219-1.","journal-title":"Sports Med."},{"issue":"9","key":"1512_CR38","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1007\/s00520-019-05279-x","volume":"28","author":"A Ueno","year":"2020","unstructured":"Ueno A, Yamaguchi K, Sudo M, Imai S. Sarcopenia as a risk factor of severe laboratory adverse events in breast cancer patients receiving perioperative epirubicin plus cyclophosphamide therapy. Support Care Cancer. 2020;28(9):4249\u201354. https:\/\/doi.org\/10.1007\/s00520-019-05279-x.","journal-title":"Support Care Cancer."},{"issue":"3","key":"1512_CR39","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s10549-020-05731-1","volume":"182","author":"GFP Aleixo","year":"2020","unstructured":"Aleixo GFP, Shachar SS, Deal AM, et al. The association of body composition parameters and adverse events in women receiving chemotherapy for early breast cancer. Breast Cancer Res Treat. 2020;182(3):631\u201342. https:\/\/doi.org\/10.1007\/s10549-020-05731-1.","journal-title":"Breast Cancer Res Treat."},{"key":"1512_CR40","doi-asserted-by":"publisher","first-page":"153303382211065","DOI":"10.1177\/15330338221106529","volume":"21","author":"J Thanestada","year":"2022","unstructured":"Thanestada J, Srinonprasert V, Nimmannit A, Korphaisarn K, Pramyothin P, Akewanlop C. Low fat-free mass index measured by bioelectrical impedance analysis correlates with hematologic adverse events in early-stage breast cancer patients receiving chemotherapy: a prospective observational cohort study. Technol Cancer Res Treat. 2022;21:15330338221106529. https:\/\/doi.org\/10.1177\/15330338221106529.","journal-title":"Technol Cancer Res Treat."},{"issue":"2","key":"1512_CR41","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1001\/jamaoncol.2019.4668","volume":"6","author":"EM Cespedes Feliciano","year":"2020","unstructured":"Cespedes Feliciano EM, Chen WY, Lee V, et al. Body composition, adherence to anthracycline and taxane-based chemotherapy, and survival after nonmetastatic breast cancer. JAMA Oncol. 2020;6(2):264\u201370. https:\/\/doi.org\/10.1001\/jamaoncol.2019.4668.","journal-title":"JAMA Oncol."},{"issue":"12","key":"1512_CR42","first-page":"5655","volume":"33","author":"S Gou\u00e9rant","year":"2013","unstructured":"Gou\u00e9rant S, Leheurteur M, Chaker M, et al. A higher body mass index and fat mass are factors predictive of docetaxel dose intensity. Anticancer Res. 2013;33(12):5655\u201362.","journal-title":"Anticancer Res."},{"issue":"2","key":"1512_CR43","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s10549-020-06061-y","volume":"186","author":"GFP Aleixo","year":"2021","unstructured":"Aleixo GFP, Yu H, Chen YT, et al. Myosteatosis evaluation using erector spinae and psoas muscles to predict adverse events during adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2021;186(2):487\u201395. https:\/\/doi.org\/10.1007\/s10549-020-06061-y.","journal-title":"Breast Cancer Res Treat."},{"issue":"3","key":"1512_CR44","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1158\/1078-0432.CCR-16-0940","volume":"23","author":"SS Shachar","year":"2017","unstructured":"Shachar SS, Deal AM, Weinberg M, et al. Skeletal muscle measures as predictors of toxicity, hospitalization, and survival in patients with metastatic breast cancer receiving taxane-based chemotherapy. Clin Cancer Res. 2017;23(3):658\u201365. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0940.","journal-title":"Clin Cancer Res."},{"issue":"14","key":"1512_CR45","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1158\/1078-0432.CCR-16-2266","volume":"23","author":"SS Shachar","year":"2017","unstructured":"Shachar SS, Deal AM, Weinberg M, et al. Body composition as a predictor of toxicity in patients receiving anthracycline and taxane-based chemotherapy for early-stage breast cancer. Clin Cancer Res. 2017;23(14):3537\u201343. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2266.","journal-title":"Clin Cancer Res."},{"issue":"2","key":"1512_CR46","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s10549-018-5014-5","volume":"173","author":"MMGA van den Berg","year":"2019","unstructured":"van den Berg MMGA, Kok DE, Posthuma L, et al. Body composition is associated with risk of toxicity-induced modifications of treatment in women with stage I-IIIB breast cancer receiving chemotherapy. Breast Cancer Res Treat. 2019;173(2):475\u201381. https:\/\/doi.org\/10.1007\/s10549-018-5014-5.","journal-title":"Breast Cancer Res Treat."},{"issue":"1","key":"1512_CR47","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s10549-014-2843-8","volume":"144","author":"AL Wong","year":"2014","unstructured":"Wong AL, Seng KY, Ong EM, et al. Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian breast cancer patients. Breast Cancer Res Treat. 2014;144(1):143\u201352. https:\/\/doi.org\/10.1007\/s10549-014-2843-8.","journal-title":"Breast Cancer Res Treat."},{"issue":"5","key":"1512_CR48","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12(5):489\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(10)70218-7.","journal-title":"Lancet Oncol."},{"issue":"9","key":"1512_CR49","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1200\/JCO.1996.14.9.2590","volume":"14","author":"H Gurney","year":"1996","unstructured":"Gurney H. Dose Calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol. 1996;14(9):2590\u2013611. https:\/\/doi.org\/10.1200\/JCO.1996.14.9.2590.","journal-title":"J Clin Oncol."},{"issue":"9","key":"1512_CR50","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1080\/17512433.2017.1347503","volume":"10","author":"JJ Hopkins","year":"2017","unstructured":"Hopkins JJ, Sawyer MB. A review of body composition and pharmacokinetics in oncology. Expert Rev Clin Pharmacol. 2017;10(9):947\u201356. https:\/\/doi.org\/10.1080\/17512433.2017.1347503.","journal-title":"Expert Rev Clin Pharmacol."},{"issue":"4","key":"1512_CR51","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.clnu.2017.07.010","volume":"37","author":"F Pamoukdjian","year":"2018","unstructured":"Pamoukdjian F, Bouillet T, L\u00e9vy V, Soussan M, Zelek L, Paillaud E. Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: a systematic review. Clin Nutr. 2018;37(4):1101\u201313. https:\/\/doi.org\/10.1016\/j.clnu.2017.07.010.","journal-title":"Clin Nutr."},{"key":"1512_CR52","doi-asserted-by":"publisher","first-page":"100154","DOI":"10.1016\/j.ctarc.2019.100154","volume":"21","author":"F Rossi","year":"2019","unstructured":"Rossi F, Valdora F, Bignotti B, Torri L, Succio G, Tagliafico AS. Evaluation of body computed tomography-determined sarcopenia in breast cancer patients and clinical outcomes: a systematic review. Cancer Treat Res Commun. 2019;21:100154. https:\/\/doi.org\/10.1016\/j.ctarc.2019.100154.","journal-title":"Cancer Treat Res Commun."},{"key":"1512_CR53","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.radonc.2020.03.014","volume":"147","author":"MI van Rijn-Dekker","year":"2020","unstructured":"van Rijn-Dekker MI, van den Bosch L, van den Hoek JGM, et al. Impact of sarcopenia on survival and late toxicity in head and neck cancer patients treated with radiotherapy. Radiother Oncol. 2020;147:103\u201310. https:\/\/doi.org\/10.1016\/j.radonc.2020.03.014.","journal-title":"Radiother Oncol."},{"issue":"7","key":"1512_CR54","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.12998\/wjcc.v8.i7.1188","volume":"8","author":"O Vergara-Fernandez","year":"2020","unstructured":"Vergara-Fernandez O, Trejo-Avila M, Salgado-Nesme N. Sarcopenia in patients with colorectal cancer: a comprehensive review. World J Clin Cases. 2020;8(7):1188\u2013202. https:\/\/doi.org\/10.12998\/wjcc.v8.i7.1188.","journal-title":"World J Clin Cases."},{"key":"1512_CR55","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.tipsro.2020.10.001","volume":"16","author":"M Anjanappa","year":"2020","unstructured":"Anjanappa M, Corden M, Green A, et al. Sarcopenia in cancer: risking more than muscle loss. Tech Innov Patient Support. Radiat Oncol. 2020;16:50\u20137. Published 2020 Nov 9. https:\/\/doi.org\/10.1016\/j.tipsro.2020.10.001.","journal-title":"Radiat Oncol."},{"key":"1512_CR56","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","volume":"57","author":"SS Shachar","year":"2016","unstructured":"Shachar SS, Williams GR, Muss HB, Nishijima TF. Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer. 2016;57:58\u201367. https:\/\/doi.org\/10.1016\/j.ejca.2015.12.030.","journal-title":"Eur J Cancer."},{"key":"1512_CR57","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2147\/CMAR.S40601","volume":"6","author":"MY Ho","year":"2014","unstructured":"Ho MY, Mackey JR. Presentation and management of docetaxel-related adverse effects in patients with breast cancer. Cancer Manag Res. 2014;6:253\u20139. Published 2014 May 27. https:\/\/doi.org\/10.2147\/CMAR.S40601.","journal-title":"Cancer Manag Res."},{"issue":"6","key":"1512_CR58","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1634\/theoncologist.2018-0590","volume":"24","author":"KA Nyrop","year":"2019","unstructured":"Nyrop KA, Deal AM, Shachar SS, et al. Patient-reported toxicities during chemotherapy regimens in current clinical practice for early breast cancer. Oncologist. 2019;24(6):762\u201371. https:\/\/doi.org\/10.1634\/theoncologist.2018-0590.","journal-title":"Oncologist."},{"key":"1512_CR59","doi-asserted-by":"publisher","first-page":"106535","DOI":"10.1016\/j.intimp.2020.106535","volume":"84","author":"K Barzaman","year":"2020","unstructured":"Barzaman K, Karami J, Zarei Z, et al. Breast cancer: biology, biomarkers, and treatments. Int Immunopharmacol. 2020;84:106535. https:\/\/doi.org\/10.1016\/j.intimp.2020.106535.","journal-title":"Int Immunopharmacol."},{"issue":"Suppl 3","key":"1512_CR60","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1634\/theoncologist.10-90003-20","volume":"10","author":"J O'Shaughnessy","year":"2005","unstructured":"O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005;10(Suppl 3):20\u20139. https:\/\/doi.org\/10.1634\/theoncologist.10-90003-20.","journal-title":"Oncologist."},{"issue":"8","key":"1512_CR61","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"ML Citron","year":"2003","unstructured":"Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741 [published correction appears in J Clin Oncol. 2003 Jun 1;21(11):2226]. J Clin Oncol. 2003;21(8):1431\u20139. https:\/\/doi.org\/10.1200\/JCO.2003.09.081.","journal-title":"J Clin Oncol."}],"container-title":["Journal of Cancer Survivorship"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-023-01512-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11764-023-01512-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11764-023-01512-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T01:55:54Z","timestamp":1747274154000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11764-023-01512-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,11]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1512"],"URL":"https:\/\/doi.org\/10.1007\/s11764-023-01512-z","relation":{},"ISSN":["1932-2259","1932-2267"],"issn-type":[{"value":"1932-2259","type":"print"},{"value":"1932-2267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,11]]},"assertion":[{"value":"7 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}